CitraSol HF-CIT-PRE ™

CitraSol HF-CIT-PRE ™ är en färdigblandad hemofiltrationsvätska med citrat för användning som pre-delution vid CRRT. Ersättningsvätska och antikoagulation i en produkt. Citratet ger regional koagulation i den extrakorporeala kretsen utan att påverka patienten.

  • Användningen av citrat minskar risken för blödning och ger ingen systemisk effekt
  • Ökar filtrets livslängd
  • Enkelt protokoll för användning
  • Kan användas på alla CRRT-maskiner
  • Ingen acidos / alkalos av CitraSol HF CIT PRE ™: isoton lösning
  • Ingen hypo- eller hypernatremi av CitraSol HF CIT PRE ™: isoton lösning

Produktsammansättning (mmol/l):

Na⁺                      139.9                  Cl⁻                       104.0

K⁺                             3.0                  Glykos                    5.0

Mg⁺⁺                       0.5                  Citrat⁻ ⁻ ⁻            13.3

CitraSol HF-CIT-PRE ™ levereras i 5L påse.

CitraSol HF-CIT-PRE ™

 

Litteratur

1) L. Schilder, et al: Citrate anticoagulation versus systemic heparinisation in continuous venovenous haemofiltration in critically ill patients with acute kidney injury: a multi-center randomized clinical trial. Critical Care 2014;16;18:472

2) L. Schilder: General discussion and future perspectives. Thesis: Regional citrate anticoagulation in continuous venovenous haemofiltration in critically ill patients with acute kidney injury. ISBN 978-94-6233-052-8. 2015:146

3) L. Schilder, et al: Coagulation, fibrinolysis and inhibitors in failing filters during continuous venovenous haemofiltration in critically ill patients with acute kidney injury: effect of anticoagulation modalities. Blood Purif. 2015;39:297-305

4) J. Aman, et al: Metabolic effects of citrate- vs bicarbonate-based substitution fluid in continuous venovenous hemofiltration: A prospective sequential cohort study. Journal of Critical Care 2010;25:120-127

5) P. Faybik, et al: Regional citrate anticoagulation in patients with liver failure supported by a molecular absorbent recirculating system. Crit Care Med 2011, 39:273-279

6) H.M. Oudemans-van Straaten, et al: Citrate anticoagulation for continuous venovenous hemofiltration. Crit Care Med 2009, 37:545-552

7) L. Schilder, et al: Citrate confers less filter-induced complement activation and neutrophil degranulation than heparin when used for anticoagulation during continuous venovenous haemofiltration in critically ill patients. BMC Nephrol. 2014;15:19

8) M. Gritters, et al: Citrate anticoagulation abolishes degranulation of polymorphonuclear cells and platelets and reduces oxidative stress during haemodialysis. Nephrol Dial Transplant 2006, 21:53-159

9) MEDICAL DEVICES: Guidance document. MEDDEV 2.1/3 rev 3, december 2009

10) Samenvatting van de produktkenmerken (SmPC), juni 2015